ADAM17 Rabbit Recombinant mAb Datasheet

生物描述

特异性	ADAM17 Rabbit Recombinant mAb detects endogenous level of total ADAM17.
背景	A disintegrin and metalloproteinase 17 (ADAM17) is a major sheddase of membrane-anchored cytokines, cell adhesion molecules, receptors, ligands, and enzymes, such as tumor necrosis factor-α (TNF-α), transforming growth factor-α, TNF-α receptor 1 (TNFR1), TNF-α receptor 2 (TNFR2), and interleukin-6 receptor, L-selectin, Notch, and angiotensin-converting enzyme type 2, in which way ADAM17 could modulate a variety of signaling transduction and affect cell behavior. ADAM17 is regarded as a first line of defense against injury and infection, by releasing tumor necrosis factor α (TNFα) to promote inflammation and epidermal growth factor (EGF) receptor ligands to maintain epidermal barrier function. It is rapidly activated by a great variety of stimuli to induce the shedding and release of soluble TNFα and the EGFR ligands amphiregulin, epiregulin, heparin-binding EGF-like growth factor, and transforming growth factor α (TGFα). ADAM17 appears to have at least as many substrates as ADAM10 which include Notch cell fate regulators, amyloid precursor protein (APP), cellular prion protein, epidermal growth factor receptor (EGFR) ligands betacellulin and EGF, adhesion molecules E-cadherin, N-cadherin, VE-cadherin and CD44, transmembrane chemokines CX3CL1 and CXCL16, the low-affinity immunoglobulin E receptor CD23, and vascular endothelial growth factor receptor 2. Other ADAM17 substrates include the adhesion molecules ICAM-1, L-selectin, and TNF receptor family members TNFRI, TNFRII.

特异性

ADAM17 Rabbit Recombinant mAb detects endogenous level of total ADAM17.

背景

A disintegrin and metalloproteinase 17 (ADAM17) is a major sheddase of membrane-anchored cytokines, cell adhesion molecules, receptors, ligands, and enzymes, such as tumor necrosis factor-α (TNF-α), transforming growth factor-α, TNF-α receptor 1 (TNFR1), TNF-α receptor 2 (TNFR2), and interleukin-6 receptor, L-selectin, Notch, and angiotensin-converting enzyme type 2, in which way ADAM17 could modulate a variety of signaling transduction and affect cell behavior. ADAM17 is regarded as a first line of defense against injury and infection, by releasing tumor necrosis factor α (TNFα) to promote inflammation and epidermal growth factor (EGF) receptor ligands to maintain epidermal barrier function. It is rapidly activated by a great variety of stimuli to induce the shedding and release of soluble TNFα and the EGFR ligands amphiregulin, epiregulin, heparin-binding EGF-like growth factor, and transforming growth factor α (TGFα). ADAM17 appears to have at least as many substrates as ADAM10 which include Notch cell fate regulators, amyloid precursor protein (APP), cellular prion protein, epidermal growth factor receptor (EGFR) ligands betacellulin and EGF, adhesion molecules E-cadherin, N-cadherin, VE-cadherin and CD44, transmembrane chemokines CX3CL1 and CXCL16, the low-affinity immunoglobulin E receptor CD23, and vascular endothelial growth factor receptor 2. Other ADAM17 substrates include the adhesion molecules ICAM-1, L-selectin, and TNF receptor family members TNFRI, TNFRII.

使用信息

抗体应用

WB, IF,ELISA,ELISA

稀释比例

WB	IF
1:1000	1:50

反应性

Human Mouse Rat

MW (kDa)

100kDa

抗体类型

Rabbit

储存液配方

10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide.

储存条件
(自收到货起)

Store at –20°C.

文献参考

Application Data

WB

Validated by Selleck

IF

Validated by Selleck